vs
Side-by-side financial comparison of AerSale Corp (ASLE) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $90.9M, roughly 1.4× AerSale Corp). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -4.0%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 0.2%).
AerSale, Inc. is a Doral, Florida-based global supplier of aftermarket commercial jet aircraft, engines, used materials, and aeronautical engineering services to passenger and cargo airlines, government, multinational original equipment manufacturers, and independent MROs. AerSale is a member of the Aircraft Fleet Recycling Association.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
ASLE vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $90.9M | $129.7M |
| Net Profit | $5.4M | — |
| Gross Margin | 34.1% | 98.0% |
| Operating Margin | 7.8% | -25.0% |
| Net Margin | 5.9% | — |
| Revenue YoY | -4.0% | 73.4% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $0.10 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $90.9M | $129.7M | ||
| Q3 25 | $71.2M | $164.9M | ||
| Q2 25 | $107.4M | $114.4M | ||
| Q1 25 | $65.8M | $81.7M | ||
| Q4 24 | $94.7M | $74.8M | ||
| Q3 24 | $82.7M | $62.9M | ||
| Q2 24 | $77.1M | $54.1M | ||
| Q1 24 | $90.5M | $41.4M |
| Q4 25 | $5.4M | — | ||
| Q3 25 | $-120.0K | $25.7M | ||
| Q2 25 | $8.6M | $-12.8M | ||
| Q1 25 | $-5.3M | $-41.2M | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $509.0K | $-54.8M | ||
| Q2 24 | $-3.6M | $-70.4M | ||
| Q1 24 | $6.3M | $-136.1M |
| Q4 25 | 34.1% | 98.0% | ||
| Q3 25 | 30.2% | 99.0% | ||
| Q2 25 | 32.9% | 98.7% | ||
| Q1 25 | 27.3% | 94.3% | ||
| Q4 24 | 31.4% | 96.6% | ||
| Q3 24 | 28.6% | 97.4% | ||
| Q2 24 | 28.2% | 96.2% | ||
| Q1 24 | 31.8% | 96.4% |
| Q4 25 | 7.8% | -25.0% | ||
| Q3 25 | 4.0% | 15.1% | ||
| Q2 25 | 11.7% | -11.1% | ||
| Q1 25 | -10.1% | -52.2% | ||
| Q4 24 | 5.2% | -81.2% | ||
| Q3 24 | 2.4% | -89.3% | ||
| Q2 24 | -2.4% | -125.1% | ||
| Q1 24 | 5.2% | -336.5% |
| Q4 25 | 5.9% | — | ||
| Q3 25 | -0.2% | 15.6% | ||
| Q2 25 | 8.0% | -11.1% | ||
| Q1 25 | -8.0% | -50.4% | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 0.6% | -87.1% | ||
| Q2 24 | -4.7% | -130.1% | ||
| Q1 24 | 6.9% | -328.9% |
| Q4 25 | $0.10 | $0.04 | ||
| Q3 25 | $0.00 | $0.28 | ||
| Q2 25 | $0.18 | $-0.14 | ||
| Q1 25 | $-0.10 | $-0.47 | ||
| Q4 24 | $0.05 | $-0.71 | ||
| Q3 24 | $0.01 | $-0.70 | ||
| Q2 24 | $-0.07 | $-0.91 | ||
| Q1 24 | $0.12 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.4M | $93.0M |
| Total DebtLower is stronger | $1.3M | — |
| Stockholders' EquityBook value | $424.4M | $114.8M |
| Total Assets | $640.5M | $605.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.4M | $93.0M | ||
| Q3 25 | $5.3M | $110.9M | ||
| Q2 25 | $5.7M | $75.2M | ||
| Q1 25 | $4.7M | $61.9M | ||
| Q4 24 | $4.7M | $58.5M | ||
| Q3 24 | $9.8M | $36.4M | ||
| Q2 24 | $4.3M | $32.3M | ||
| Q1 24 | $2.6M | $43.3M |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $907.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $376.0K | — | ||
| Q2 24 | $522.0K | — | ||
| Q1 24 | $3.5M | — |
| Q4 25 | $424.4M | $114.8M | ||
| Q3 25 | $417.1M | $73.6M | ||
| Q2 25 | $415.9M | $32.7M | ||
| Q1 25 | $406.5M | $32.8M | ||
| Q4 24 | $455.6M | $59.1M | ||
| Q3 24 | $451.5M | $-30.5M | ||
| Q2 24 | $449.8M | $15.1M | ||
| Q1 24 | $452.0M | $74.1M |
| Q4 25 | $640.5M | $605.2M | ||
| Q3 25 | $646.3M | $538.6M | ||
| Q2 25 | $646.7M | $555.3M | ||
| Q1 25 | $646.1M | $548.8M | ||
| Q4 24 | $604.7M | $594.1M | ||
| Q3 24 | $601.5M | $504.4M | ||
| Q2 24 | $598.7M | $551.1M | ||
| Q1 24 | $571.7M | $663.5M |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.4M | $60.7M |
| Free Cash FlowOCF − Capex | $9.8M | — |
| FCF MarginFCF / Revenue | 10.8% | — |
| Capex IntensityCapex / Revenue | 1.7% | — |
| Cash ConversionOCF / Net Profit | 2.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-29.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.4M | $60.7M | ||
| Q3 25 | $-8.9M | $14.3M | ||
| Q2 25 | $19.8M | $5.0M | ||
| Q1 25 | $-45.2M | $-42.2M | ||
| Q4 24 | $37.5M | $-35.7M | ||
| Q3 24 | $10.4M | $-42.5M | ||
| Q2 24 | $-15.3M | $-40.2M | ||
| Q1 24 | $-21.5M | $-119.0M |
| Q4 25 | $9.8M | — | ||
| Q3 25 | $-9.8M | $14.2M | ||
| Q2 25 | $18.6M | — | ||
| Q1 25 | $-47.6M | — | ||
| Q4 24 | $32.3M | — | ||
| Q3 24 | $8.9M | — | ||
| Q2 24 | $-18.9M | $-40.3M | ||
| Q1 24 | $-25.0M | — |
| Q4 25 | 10.8% | — | ||
| Q3 25 | -13.8% | 8.6% | ||
| Q2 25 | 17.3% | — | ||
| Q1 25 | -72.4% | — | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | -24.6% | -74.5% | ||
| Q1 24 | -27.7% | — |
| Q4 25 | 1.7% | — | ||
| Q3 25 | 1.3% | 0.1% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | 1.9% | 0.0% | ||
| Q2 24 | 4.7% | 0.2% | ||
| Q1 24 | 3.9% | 0.0% |
| Q4 25 | 2.11× | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.89× | — | ||
| Q3 24 | 20.52× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -3.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
